<?xml version="1.0" encoding="UTF-8"?>
<p id="par0020">Yang Mingbo et al. [
 <xref rid="bib0020" ref-type="bibr">4</xref>] reported a multi-center clinical observation study of RYM improving the clinical symptoms in the treatment of COVID-19. For a 7-day treatment, the treatment group was given RYM combined with lopinavir, alpha-interferon, abidol hydrochloride and ribavirin, while the control group was given lopinavir, alpha-interferon, abidol hydrochloride and ribavirin. The remission rate of chest CT in the treatment group was 88.46 %, which was higher than the 73.91 % registered in the control group. The viral nucleic acid negative conversion rate in the treatment group was 96.15 %, which was statistically higher than that in the control group, which was of 60.87 % (P &lt; 0.01).
</p>
